

**Remarks**

The foregoing amendments to the specification are to insert the priority provisional application information, for which this application claims benefit. The Abstract has been added as a separate sheet, and should be inserted following the claims in the specification.

The amendments to the claims are to correct erroneous numbering and to place the claims in proper format. No new matter has been added.

Should the Examiner have any questions, please contact the undersigned attorney.

Respectfully submitted,

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(617) 871-3343

  
Paul J. Paglierani  
Attorney for Applicants  
Reg. No. 52,498

Date: October 13, 2005